How much funding has Tessera Therapeutics raised?

Tessera Therapeutics has raised $730.0M in total funding, most recently a Corporate Round.

When was Tessera Therapeutics founded?

Tessera Therapeutics was founded in 2018.

Where is Tessera Therapeutics headquartered?

Tessera Therapeutics is headquartered in Somerville, Massachusetts, United States.

What industry is Tessera Therapeutics in?

Tessera Therapeutics operates in Biotech, Genomics, Life Sciences, Therapeutics.

How many employees does Tessera Therapeutics have?

Tessera Therapeutics has 201-500 employees.

Tessera Therapeutics

Q: Who are Tessera Therapeutics's investors?

Tessera Therapeutics's investors include Regeneron Pharmaceuticals, Bill & Melinda Gates Foundation, Abu Dhabi Investment Authority, Temasek.

Writing a new future for medicine

Somerville, United States · Founded 2018 · $730.0M raised

Headquarters: Somerville, Massachusetts
Employees: 201–500
Founded: 2018
Business Model: B2B

Website: tesseratherapeutics.com
Total Funding: $730.0M
Last Round: $150.0M Corporate RoundDec 2025
Rounds: 4

About

Tessera Therapeutics is a Flagship Pioneering biotechnology company pioneering Gene Writing, a novel genome engineering platform that uses mobile genetic elements to make permanent, programmable changes to the human genome. Unlike CRISPR-based editing, Gene Writing can make small and large alterations without double-strand DNA breaks. The company is advancing in vivo programs for rare diseases including alpha-1 antitrypsin deficiency and sickle cell disease, with Regeneron as a key development partner.

Summary

Tessera Therapeutics is a Biotech company based in Somerville, United States, founded in 2018. It has raised $730.0M in total across 4 rounds, most recently a $150.0M Corporate Round round in Dec 2025. Investors include Regeneron Pharmaceuticals, Bill & Melinda Gates Foundation and Abu Dhabi Investment Authority.

LinkedIn X (Twitter)